Compare ADMA Biologics Inc (ADMA) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs ProShares Ultra QQQ ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while ProShares Ultra QQQ ETF trades at $92.11. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QLD | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $100.53 |
52-Week Low | $7.60 | $57.16 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
QLD trades at $92.70, up 1.16% with a bullish technical outlook supported by moving averages. The leveraged ETF shows strong momentum with RSI indicating potential overbought conditions near-term. Recent institutional buying by 180 Wealth Advisors and positive media coverage highlight tactical interest in tech-focused leveraged strategies.
As a 2x leveraged Nasdaq-100 ETF, QLD offers amplified exposure to large-cap tech but carries significant volatility risks. The fund has delivered substantial long-term returns but experienced deep drawdowns during market stress. Investors should carefully consider risk tolerance given the daily rebalancing mechanics and concentration in technology sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
